Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early Stage Triple Negative Breast Cancer

NCT07017673 is registered in ClinicalTrials.gov with Cedars-Sinai Medical Center as lead sponsor.

NCT NCT07017673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07017673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early Stage Triple Negative Breast Cancer
Lead sponsor
Cedars-Sinai Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
July 25, 2025
Completion date
November 30, 2032
Enrollment
34 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

early stage triple-negative breast carcinoma, tnbc, tnbc - triple-negative breast cancer